Trellis Bioscience
Developing native human monoclonal antibodies to treat intractable infectious diseases
$9MSeries C
Role not disclosedNS
New Science Ventures
Activity from announced rounds
Activity in this selectionSeries C+
New Science Ventures is the investment firm named by Trellis and as lead in Novadip’s financing.
Recorded funding activity
Novadip develops cell therapies and grafts for damaged tissue. Trellis develops human antibodies against difficult infectious diseases. The two companies pursue different therapeutic approaches under the same firm-level attribution.
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $9M 1 disclosed · full round size, not this investor’s share